Impact of sacubitril/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: the PARADISE-MI echocardiographic substudy
AM Shah, B Claggett, N Prasad, G Li, M Volquez… - Circulation, 2022 - Am Heart Assoc
Background: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV)
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …
enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits …
Rationale and design of a multi‐center, prospective randomized controlled trial on the effects of sacubitril–valsartan versus enalapril on left ventricular remodeling in …
K Diao, D Wang, Z Chen, X Wu, M Ma, Y Zhu… - Clinical …, 2021 - Wiley Online Library
Background Angiotensin receptor neprilysin inhibitor (ARNI) sacubitril‐valsartan has been
recommended as one of the first‐line therapies in heart failure with reduced ejection fraction …
recommended as one of the first‐line therapies in heart failure with reduced ejection fraction …
Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction
A Rezq, M Saad, M El Nozahi - The American journal of cardiology, 2021 - Elsevier
The role of sacubitril and/or valsartan in patient with heart failure (HF) is established.
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …
Whether sacubitril and/or valsartan plays a role in improving outcomes in patients after ST …
The effects of angiotensin receptor-neprilysin inhibition on major coronary events in patients with acute myocardial infarction: insights from the PARADISE-MI trial
Background: In patients who survive an acute myocardial infarction (AMI), angiotensin-
converting enzyme inhibitors decrease the risk of subsequent major cardiovascular events …
converting enzyme inhibitors decrease the risk of subsequent major cardiovascular events …
The benefits of sacubitril–valsartan in patients with acute myocardial infarction: a systematic review and meta‐analysis
B Xiong, D Nie, J Qian, Y Yao, G Yang… - ESC heart …, 2021 - Wiley Online Library
Aims We aimed to investigate whether sacubitril–valsartan could further improve the
prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute …
prognosis, cardiac function, and left ventricular (LV) remodelling in patients following acute …
[HTML][HTML] Angiotensin receptor–neprilysin inhibition in acute myocardial infarction
Background In patients with symptomatic heart failure, sacubitril–valsartan has been found
to reduce the risk of hospitalization and death from cardiovascular causes more effectively …
to reduce the risk of hospitalization and death from cardiovascular causes more effectively …
Effects of sacubitril/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction
H Wang, X Fu - Coronary artery disease, 2021 - journals.lww.com
Objective The aim of this study was to investigate the effect of sacubitril/valsartan (Sal/Val)
on left ventricular (LV) remodeling in patients with LV systolic dysfunction following acute …
on left ventricular (LV) remodeling in patients with LV systolic dysfunction following acute …
Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction …
JE Møller, U Dahlström, O Gøtzsche, A Lahiri… - American Heart …, 2004 - Elsevier
BACKGROUND: Angiotensin-converting enzyme inhibitors have been shown to attenuate
adverse remodeling after acute myocardial infarction (AMI), and the same has been …
adverse remodeling after acute myocardial infarction (AMI), and the same has been …
Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction
SD Solomon, H Skali, NS Anavekar, M Bourgoun… - Circulation, 2005 - Am Heart Assoc
Background—Angiotensin-converting enzyme (ACE) inhibitors have been shown to
attenuate left ventricular (LV) enlargement in association with reducing mortality after …
attenuate left ventricular (LV) enlargement in association with reducing mortality after …
Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits
Abstract Background: Sacubitril/valsartan (SAC/VAL) is approved by the US Food and Drug
Administration for heart failure with reduced ejection fraction (HFrEF). Objectives: This study …
Administration for heart failure with reduced ejection fraction (HFrEF). Objectives: This study …